Early and longitudinal response to sublingual immunotherapy across pediatric allergic multimorbidity…

Cohort studyPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology· Aug 2026

Early and longitudinal response to sublingual immunotherapy across pediatric allergic multimorbidity patterns: A 3-year real-world cohort study.

Victor Gonzalez-Uribe, Jimena Prieto-Gomez, Sebastian Moreno-Castro … Paola de Baro-Alvarez

Read paper

Allergy & ImmunologyCohort studyQ1IF 3.0

Asthma plus rhinitis was linked to higher odds of early sublingual immunotherapy response

Early and longitudinal response to sublingual immunotherapy across pediatric allergic multimorbidity patterns: A 3-year real-world cohort study.

Victor Gonzalez-Uribe … Paola de Baro-Alvarez

Pediatric allergy and immunology · Aug 2026 · Q1 in Pediatrics

Background

The timing of clinically meaningful benefit after pediatric sublingual immunotherapy (sublingual immunotherapy) across allergic multimorbidity patterns remains uncertain.

Methods

This retrospective longitudinal cohort included patients aged 3-17 years who received individualized liquid-drop sublingual immunotherapy and met prespecified adherence and treatment-persistence criteria.

n = 1208 patients

Results

asthma plus rhinitis had far higher odds of early sublingual immunotherapy response than asthma alone

aOR 4.73 (95% CI 3.47 to 6.45)

CI excludes the null - significant

More results

Among 1208 patients, 1095 had asthma and 954 allergic rhinitis.

Overall, 666/1095 (60.8%) achieved month-6 Pediatric Asthma Quality of Life Questionnaire MCID: 515/671 (76.8%) with asthma plus allergic rhinitis (Asthma+AR), 103/254 (40.6%) with allergic asthma without AR, and 48/170 (28.2%) with asthma, AR, and atopic dermatitis (Asthma+AR + AD).

More results

By month 36, mean Pediatric Asthma Quality of Life Questionnaire increased by 1.42 points, rhinitis-related quality-of-life scores decreased by 1.89 points, FeNO decreased by 15.7 ppb, and prescribed inhaled corticosteroid dose decreased by 92.6%.

“

Conclusion

Early response to pediatric sublingual immunotherapy differed across clinical allergic multimorbidity patterns, although outcomes continued to improve through 36 months in this selected adherent and treatment-persistent cohort.

Early and longitudinal response to sublingual immunotherapy across pediatric allergic multimorbidity patterns: A 3-year real-world cohort study.

Early and longitudinal response to sublingual immunotherapy across pediatric allergic multimorbidity patterns: A 3-year real-world cohort study.

Related papers